Drug
Moxonidine clinical trials
- studies test it
- 19
- open now
- 1
- in phase 3
- 2
- first study started
- 2002
Keep track of what changes. Save the moxonidine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
19 studies that test it; most in 2012 (4)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 4 |
| 2015 | 3 |
| 2019 | 2 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 2
- Phase 2
- 1
- Phase 3
- 2
- Phase 4
- 11
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 18
Baker Heart and Diabetes Institute (5) · Vanderbilt University Medical Center (3) · Royal Perth Hospital (2) · Aristotle University Of Thessaloniki (1) · National Research Center for Preventive Medicine (1) · Spyridon Deftereos (1) · UMC Utrecht (1) · Solvay Pharmaceuticals (1)
Often tested with
Tested in the same studies.
Hydrochlorothiazide (2) · Aliskiren (1) · Lercanidipine (1) · Valsartan (1) · Nicorandil (1) · Doxazosin (1) · Pindolol (1) · Amiloride (1)
Studies
Open first, then newest update. How each study uses moxonidine is read from its arms, and is right about nine times in ten.
Testing it · 19
- Sympathetic Mechanisms in Obesity-Crossover DesignRecruitingPhase 1/2Vanderbilt University Medical CenterNCT05312892Written as Moxonidine
- Autonomic Determinants of POTS - Pilot1Active, not recruitingEarly Phase 1Vanderbilt University Medical CenterNCT04050410Written as Moxonidine
- Autonomic Determinants of POTS - Pilot 2Active, not recruitingEarly Phase 1Vanderbilt University Medical CenterNCT04140721Written as Moxonidine Pill
- Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of ObesityTerminatedPhase 1Italo BiaggioniNCT04329806Written as Moxonidine 0.2 MG
- Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney DiseaseCompletedPhase 4Baker Heart and Diabetes InstituteNCT01094769Written as Moxonidine
- Role of Sympathetic Activation in Ischemia Reperfusion InjuryCompletedPhase 4Royal Perth HospitalNCT04479813Written as Moxonidine 0.2 MG
- Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related HypertensionStatus unknownPhase 4Royal Perth HospitalNCT04474899Written as Moxonidine 0.4 MG
- Moxonidine Effects on Neuropeptide YCompletedPhase 4Aristotle University Of ThessalonikiNCT05147753Written as Moxonidine
- Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal WomenCompletedNot applicableNational Research Center for Preventive MedicineNCT02355821Written as Moxonidine
- Moxonidine + Perindopril in Hypertensive Patients With Metabolic SyndromeStatus unknownPhase 4Sergey V. NedogodaNCT04023565Written as perindopril + moxonidine
- Alleviating the Metabolic Side Effects of Antipsychotic MedicationsWithdrawnPhase 4Baker Heart and Diabetes InstituteNCT01567124Written as Moxonidine
- Polycystic Ovary Syndrome - Improving OutcomesCompletedPhase 4Baker Heart and Diabetes InstituteNCT01504321Written as Moxonidine
- Moxonidine for Prevention of Post-ablation AFib RecurrencesCompletedPhase 4Spyridon DeftereosNCT01791699Written as Moxonidine
- Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With ObesityStatus unknownPhase 4Baker Heart and Diabetes InstituteNCT01180231Written as Moxonidine (Physiotens)
- Treatment of Adiposity Related hypErTension (TARGET)CompletedPhase 4UMC UtrechtNCT01138423Written as Moxonidine
- The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and HypertensionStatus unknownPhase 4Baker Heart and Diabetes InstituteNCT01360710Written as Moxonidine
- Moxonidine in Patients Undergoing Vascular SurgeryTerminatedPhase 3University Hospital, Basel, SwitzerlandNCT00244504Written as moxonidine
- Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina PectorisTerminatedNot applicableUniversity of AarhusNCT00424801Written as Moxonidin
- Efficacy and Safety of Moxonidine in Indian PatientsCompletedPhase 3Solvay PharmaceuticalsNCT00160277Written as Moxonidine
Codes
What other systems call moxonidine · ClinicalTrials.gg INT003178
- MeSH (NLM) C043482moxonidineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) CC6X0L40GWMOXONIDINEConfirmed FDA, NLM, Wikidata
- RxNorm 30257Confirmed FDA, Wikidata
- Wikidata Q419944moxonidineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C87629MoxonidineOne source FDA
- DrugBank DB09242One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C043482 | moxonidine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | CC6X0L40GW | MOXONIDINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 30257 | — | Confirmed FDA, Wikidata |
| Wikidata | Q419944 | moxonidine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C87629 | Moxonidine | One source FDA |
| DrugBank | DB09242 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.